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Retinitis pigmentosa (RP) is a major cause of blindness that affects 1.5 million people
worldwide. Mutations in cyclic nucleotide-gated channel b 1 (CNGB1) cause approximately
4% of autosomal recessive RP. Gene augmentation therapy shows promise for treating
inherited retinal degenerations; however, relevant animal models and biomarkers of
progression in patients with RP are needed to assess therapeutic outcomes. Here, we
evaluated RP patients with CNGB1 mutations for potential biomarkers of progression and
compared human phenotypes with those of mouse and dog models of the disease.
Additionally, we used gene augmentation therapy in a CNGb1-deficient dog model to
evaluate potential translation to patients. CNGB1-deficient RP patients and mouse and dog
models had a similar phenotype characterized by early loss of rod function and slow rod
photoreceptor loss with a secondary decline in cone function. Advanced imaging showed
promise for evaluating RP progression in human patients, and gene augmentation using
adeno-associated virus vectors robustly sustained the rescue of rod function and preserved
retinal structure in the dog model. Together, our results reveal an early loss of rod function in
CNGB1-deficient patients and a wide window for therapeutic intervention. Moreover, the
identification of potential biomarkers of outcome measures, availability of relevant animal
models, and robust functional rescue from gene augmentation therapy support future work
to move CNGB1-RP therapies toward clinical trials.
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Introduction
Retinitis pigmentosa (RP) is a genetically heterogeneous cause of 
blindness, affecting approximately 1 in 4,000 individuals (1). Muta-
tions for nonsyndromic RP have been identified in over 80 different 
genes (RetNet, Retinal Information Network) (2). The phenotype 
is characterized initially by decreased rod-mediated function, loss 
of dim-light vision followed by constriction of peripheral vision, 
a decrease in visual acuity and, in many instances, progression to 
legal blindness. Patients develop attenuation of superficial retinal 
blood vessels, optic disc pallor, and characteristic “bone-spicule” 
pigment clumping in the midperipheral retina (1). Currently, there 
is no cure for RP, although gene therapy approaches for other inher-
ited retinal degenerations are showing promising results in phase I 
and II clinical trials (3–11). The development of therapies for inher-
ited retinal degenerations such as RP is facilitated by relevant ani-
mal models that recapitulate the human phenotype and that can be 
used for preclinical development and refinement of therapy. Prior 
to clinical trials, it is important to also ascertain whether there are 
suitable biomarkers of progression of retinal disease that can be 
used to assess the efficacy of therapy within a practical time frame.
Mutations in the rod cyclic nucleotide-gated channel β 1 
(CNGB1) gene cause autosomal recessive RP type 45 (RP45) 
(12–23) (Supplemental Table 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI95161DS1) 
and account for approximately 4% of autosomal recessive RP 
cases (1). The CNGB1 gene codes for the β subunit (CNGβ1a) of 
the rod photoreceptor cyclic nucleotide-gated (CNG) ion chan-
nel, with additional splice variants being expressed in the retina 
(glutamic acid–rich proteins 1 and 2 [GARP1 and GARP2]), olfac-
tory sensory neurons (CNGβ1b), and other tissues (24). Rod pho-
toreceptor CNG channels are nonspecific cation channels in the 
outer segment cell membrane consisting of 3 cyclic nucleotide- 
gated channel α 1 (CNGα1) subunits and 1 CNGβ1a subunit (24, 25). 
CNGβ1a is important for the trafficking of the channel to the out-
er segment, its positioning within the cell membrane, and control 
of the channel’s temporal activity (see ref. 26 for a review). Bind-
ing of cyclic GMP (cGMP) in the dark results in transient opening 
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20/20 to 20/100 and remained largely stable over time. Visu-
al fields were constricted to 2 to 18 degrees within the macula. 
Ophthalmic evaluations of patients 5, 6, 7, and 8 revealed poste-
rior subcapsular cataracts, a waxy pallor appearance of the optic 
disc, cystoid macular edema, and severe attenuation of the ret-
inal vasculature (Figure 1, B–D, white arrowheads). We observed 
“bone-spicule” intraretinal pigment migration in the mid- 
peripheral retina of patients 3–8. Patient 1 (Figure 1A) and patient 
2 presented at an earlier disease stage and did not show changes 
typical of retinal degeneration on fundoscopy. An autofluores-
cence (AF) ring of variable size (indicative of lipofuscin accumula-
tion) was apparent on fundus autofluorescence (FAF) imaging cir-
cumscribing an area of relatively functional retina (Figure 1, A–D, 
insets, and Figure 2A). The average rate of AF ring constriction var-
ied with size. Patient 1 had the largest ring (68.99 mm2 in the right 
eye at baseline), which progressed at a loss of 14.32 mm2 by year 2 
and 8.01 mm2 by year 5 (Figure 2B and Supplemental Figure 2A). 
Patients with smaller rings (<10 mm2) had constriction at a slower 
rate: patient 6 had lost 1.69 mm2 by year 2. Quantitative thickness 
maps generated from 19 spectral domain optical coherence tomog-
raphy (SD-OCT) raster scans of the photoreceptor-attributable 
layers between the vitread boundary of the outer nuclear layer 
(ONL) and the Bruch’s membrane–choroidal interface (recep-
tor + [REC+] layer) revealed significant thinning in the perifoveal 
regions over time (Figure 2C). The maps in are scaled according to 
the reported range of REC+ layer thickness in healthy eyes (>150 
μm, white color) (32). The respective REC+ layer thicknesses in all 3 
patients were uniformly decreased in areas closer to the fovea than 
to the position of ellipsoid zone (EZ) disruption and the border 
of the AF ring. The extent of thinning progressed gradually from 
approximately 125 μm (red) to the approximately 60-μm (green) 
region, where the border of the AF ring was positioned (Figure 2). 
Profiles of REC+ thickness in a single SD-OCT scan in each patient 
indicated that the observed thinning within the area circumscribed 
by the AF ring fell below the 95% CIs of healthy, age-matched eyes 
(Supplemental Figure 2B). ). Each profile also showed significant 
central thickening of REC+ (>95% CIs of healthy eyes) within the 
central 1-mm diameter of the foveal region. Thickness peaked at 
the foveal center in all cases and remained stable over time rela-
tive to the peripheral thinning near the edge of observable degen-
eration or the border of the AF ring. Analysis of the of individual 
SD-OCT scans revealed unusual but consistent characteristics in 
all patients that included a shallow foveal pit, continuous lamina-
tion of the plexiform layers, and widening of the ONL at the center 
(Supplemental Figure 3).
Full-field electroretinogram (ffERG) testing revealed gener-
alized dysfunction of rods in all patients. Scotopic responses were 
nonrecordable in the older patients (patients 5–8) and attenuated 
in the younger patients (patients 1–4). Attenuated 30-Hz flicker 
and single-flash photopic responses were also evident in the older 
patients (patients 5–8), while we detected only marginally decreased 
photopic responses and implicit time delays in the younger patients 
(patients 1–4) (Table 1 and Supplemental Figure 2C).
Cngb1–/– mice show a progressive loss of retinal thickness with a 
slow loss of cones. Cngb1–/– (Cngb1-X26) mice have progressive reti-
nal thinning accompanied by a progressive loss of photoreceptors 
and their function (Figure 3). We measured the age-related loss 
of the CNG channel and rod photoreceptor depolarization. With 
light-induced activation of the phototransduction cascade, there 
is a reduction in cGMP levels mediated by the G protein activation 
of a phosphodiesterase (PDE6). Reduced cGMP leads to closure of 
the channels and hyperpolarization of the rod.
Some phenotyping of patients with RP45 has been previously 
published and typically describes night blindness from childhood 
and a later-onset of loss of peripheral vision, leading to an RP diag-
nosis at around 30 years of age and legal blindness by 60 years of 
age (12, 13, 16, 18, 22).
A mouse model, Cngb1-X26, generated by excising exon 
26 and resulting in loss of the full- length CNGβ1a protein, was 
reported to have a significant decrease in rod function and retinal 
degeneration (27). Gene augmentation therapy was shown to res-
cue the phenotype in this model (28).
Recently, we identified a spontaneous mutation in canine 
Cngb1 in dogs with recessively inherited progressive retinal degen-
eration (29). Early loss of rod vision and slow photoreceptor degen-
eration were observed (29). The canine mutation is downstream 
of the Garp region and results in a lack of full-length Cngb1a, thus 
modeling the majority of reported RP45 cases and closely resem-
bling the Cngb1-X26 mouse model.
Here, we demonstrate that detailed advanced retinal imaging 
shows promise with regard to outcome measures for a CNGβ1-RP 
therapy trial. Moreover, our detailed phenotypic analysis demon-
strates that the 2 preclinical models with Cngb1 mutations reca-
pitulate the human RP45 phenotype. Finally, we report that gene 
therapy to introduce a normal copy of canine Cngb1a into the rod 
photoreceptors results in robust, sustained restoration of rod func-
tion and retinal structural preservation in Cngb1–/– dogs and rep-
resents what we believe to be an important preclinical step toward 
gene augmentation therapy for human RP45.
Results
Human patients with RP45 show early loss of night vision and a slowly 
progressive photoreceptor degeneration. Clinical and genetic charac-
teristics of each patient are summarized in Table 1. The cohort (n = 
8) consists of 4 sporadic cases and 2 sibling pairs, with a mean age 
of 37.1 years (range, 14–70 years). Five of the patients are of Euro-
pean descent (patients 3–6 and 8) and three are Hispanic (patients 
1, 2, and 7). A total of 8 different CNGB1 mutations were identified. 
Three of the mutations had been previously described in RP45 
patients: c.2284C>T, p.Arg762Cys (16, 30); c.1896C>A, p.Cys632* 
(15); c.3150delG; and p.Phe1051Leufs*12 (15, 22). Five novel 
mutations (1 nonsense, 2 frameshift, and 2 intronic/splice) were 
detected: c.2508C>A, p.Tyr836*; c.522_523insC, p.Lys175Glnfs*4; 
c.2544_2545insC, p.Leu849Profs*3; c.1122-9G>A; c.2218-2A>G 
(Table 1 and Supplemental Table 1). The 2 novel intronic muta-
tions were found in patient 4. c.2218-2A>G resides in a canonical 
splice acceptor site. c1122-9G>A is predicted by Human Splicing 
Finder software (31) to introduce a strong new splice acceptor site 
that would insert an additional 7 bp to the 5′ end of exon 15, with a 
resulting frameshift and predicted premature stop codon. We per-
formed a minigene assay and confirmed the predicted alteration in 
splicing and the resulting frameshift (Supplemental Figure 1).
All patients had childhood-onset nyctalopia but on presen-
tation had best-corrected visual acuity (BCVA) ranging from 
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in canine Cngb1 (29) (c.2387delA;2389_2390 
insAGCTAC; Supplemental Figure 4, A and B) 
and direct Sanger sequencing showed that the 
mutation caused skipping of exon 26 (data not 
shown), introducing a premature stop codon 
early in exon 27 (Supplemental Figure 4C). The 
truncated product partly escaped nonsense- 
mediated decay, leading to a relative expression 
level approximately 40% of that of WT tran-
script levels in the controls (Supplemental Figure 
5A). There was a complete absence of full-length 
CNGβ1 in the photoreceptors of Cngb1–/– dogs (29), 
but IHC using an antibody that targets CNGβ1 
between the N-terminal GARP region and the pre-
dicted mutation site revealed an accumulation of 
truncated protein within the inner segments (Sup-
plemental Figure 5B).
Cngb1–/– dogs have slow photoreceptor loss and 
relative preservation of cones. Color fundus imaging 
revealed an initial hyporeflective appearance of 
the fundus in the tapetal area, which, with progres-
sion, was accompanied by mild attenuation of the 
superficial retinal vasculature and eventually obvi-
ous signs of retinal thinning (tapetal hyperreflec-
tivity; Supplemental Figure 6A). On FAF imaging, a 
region of AF appeared in the center of the area cen-
tralis of a Cngb1–/– dog at approximately 3 months 
of age (Supplemental Figure 6B). The area centra-
lis is the canine equivalent of the human macula 
(33). The earliest change detectable by SD-OCT 
in Cngb1–/– puppies was a loss of definition of the 
zones between the external limiting membrane 
(ELM) and the interdigitation zone (IZ) in the 
periphery from 3 months of age. These zones rep-
resent the photoreceptor inner and outer segments 
and interface with the retinal pigment epithelium 
(RPE). The loss of definition progressed with age, 
with the central retina remaining unaffected until 
later in the disease progression (Supplemental Fig-
ure 7). We observed slowly progressive thinning of 
the REC+ layer (which represents the entire length 
of the photoreceptors), with thinning occurring 
initially in the more peripheral retina, while the 
area centralis showed relative preservation (Figure 
4A). We further examined changes in the thick-
nesses of the different photoreceptor components that make up the 
REC+ (outer plexiform layer [OPL], ONL, ELM, myoid zone [MZ], 
EZ, outer segments, IZ, and the RPE–Bruch’s complex) (Supple-
mental Figure 8) and found that, compared with more peripheral 
retina, the center of the area centralis actually had an earlier thin-
ning of the ONL but better preservation of the zones representing 
photoreceptor inner and outer segments, which accounted for the 
overall preservation of the REC+ thickness (Figure 4A). The spatial 
preservation of REC+ not only involves the area centralis but also 
the visual streak, as shown in the heatmaps in Figure 4B. The visual 
streak is a horizontal zone of higher photoreceptor density extend-
ing temporally and nasally from the area centralis.
of outer retinal thickness (REC+ layer) by in vivo cross-sectional 
SD-OCT imaging (Figure 3A). Cngb1–/– mice showed a slowly 
progressive, almost linear thinning of the REC+ layer within the 
observed time frame of 2 to 52 weeks of age. While rod photore-
ceptors degenerated, we found that cone morphology was also 
compromised, as indicated by a loss of cone outer segments (Fig-
ure 3B). This is in keeping with the progressive loss of cone func-
tion during photoreceptor layer thinning that was detected by 
photopic ERG measurements (Figure 3C).
Mutation in Cngb1–/– dogs leads to exon skipping and expression of 
a shortened CNGB1 product. Reverse transcriptase PCR (RT-PCR) 
spanning the previously reported site of the exon 26 mutation 
Figure 1. Spectrum of disease severity in patients with CNGB1-associated RP. Color fundus 
montages and corresponding AF images of the left eye of patient 1 (p.Phe1051Leufs*12 homo-
zygous) (A), patient 6 (p.Leu849Profs*3; p.Lys175Glnfs*4) (B), and the right eyes of patient 
7 (p.Cys632*; p.Phe1051Leufs*12) (C) and patient 8 (p.Arg762Cys homozygous), illustrating 
typical presentations of RP features: (B–D) waxy pallor of the optic disc, severe attenuation 
of the retinal vasculature (white arrowheads), and bone-spicule pigment clumping in the 
mid-periphery (insets). (A) The left macula of patient 1 (p.Phe1051Leufs*12 homozygous) 
shows largely unremarkable features for retinal degeneration. REC+ thickness is defined as all 
visiblelayers between the inner nuclear layer-outer nuclear layer (INL/ONL) complex and the 
Bruch’s membrane-choroidal (BM/Choroid) interface.
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ceptors (Figure 4, C and D). With disease progression, the cone 
inner segments became initially broader (by 12 months of age) 
and then stunted (by 18 and 28 months of age). Transmission 
electron microscopy showed that in young Cngb1–/– dogs, the rod 
outer segments had uniformly stacked discs (e.g., at 8 weeks of 
age), but with disease progression, they became disorganized, 
while the morphology of the cone outer segments remained bet-
ter preserved (Figure 4E).
Retinal sections showed that there was an early disruption of 
the normally ordered demarcation between the inner segment 
and outer segment layers, with cone inner segments extending 
between the rod outer segments at as early as 2 months of age in 
the peripheral retina of Cngb1–/– dogs (Figure 4C). A progressive 
loss of rows of photoreceptor nuclei occurred, such that by 28 
to 30 months of age, only 3 to 4 rows remained in the central 
retina. We observed a relative preservation of cone photore-
Figure 2. Progressive AF ring 
constriction and photoreceptor 
layer thinning in affected patients 
homozygous and compound 
heterozygous for CNGB1 muta-
tions. Affected patients homo-
zygous for CNGB1: patients 1 and 
2 (p.Phe1051Leufs*12); affected 
patient heterozygous for CNGB1: 
patient 6 (p.Leu849Profs*3, 
p.Lys175Glnfs*4). (A) FAF imaging 
(488-nm) of the right eye in each 
patient revealed the inner and 
outer border (white arrows) of a 
progressively constricting region 
(ring), delineating the centrally pre-
served area of retinal function. (B) 
Retinal schematic illustrating the 
constriction size (mm2) and shape 
of the centrally preserved region 
over various time intervals (insets): 
after 60 months in patient 1 (red) 
and patient 2 (blue) and 20 months 
in patient 6 (green). (C) Color-coded 
maps of total REC+ thickness after 
60 months in patients 1 and 2 and 
after 20 months in patient 6 from 
a segmented macular SD-OCT scan 
within the position of the retina 
enclosed in the red rectangle (upper 
right inset). The right eye of each 
patient is shown, where white on 
the color scale (>125 μm) denotes 
the range of REC+ thickness in 
healthy eyes. REC+ thickness is 
defined as all visible layers between 
the inner nuclear layer–ONL (INL-
ONL) complex and the Bruch’s 
membrane–choroidal interface 
(SD-OCT, inset). BM, basement 
membrane.
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Cone function gradually declined with age (Figure 5). How-
ever, cone-mediated vision was well preserved, with vision of the 
Cngb1–/– dogs being comparable to that of normal control dogs 
at all lighting levels except the lowest level, which assessed rod 
vision (Figure 5, D and E).
Gene augmentation therapy in Cngb1–/– dogs restores the CNG 
channel in treated retinal regions, resulting in rod function and retinal 
preservation. A total of 8 eyes of young Cngb1–/– dogs (Supplemental 
Table 2) were used in the gene therapy study. We used an adeno- 
associated virus vector serotype 5 that delivered canine Cngb1 
under the control of a human GRK1 promoter (AAV5-hGRK-
cCgnb1) (dose details are provided in Supplemental Table 2). An ini-
tial pilot study in 1 Cngb1–/– dog (14-033, right eye [OD]) resulted in 
a small improvement in ffERG amplitudes detected 3 months after 
injection and improved performance in vision testing at the lowest 
light level (data not shown). A higher dose of the same vector in the 
second eye of the same dog resulted in a more substantial ERG res-
cue and vision testing rescue. The repeat administration of vector 
to dog 14-033 showed no indication of a resulting adverse immune 
response in clinical, SD-OCT, or IHC studies, and excellent ffERG 
and vision testing outcomes were achieved in the second eye.
An additional 6 eyes (of 4 dogs) were injected at the higher 
titer. IHC showed that CNGβ1 protein was restored to the rod out-
er segments only in the region of the subretinal injection (Figure 
6A, see also Supplemental Figure 9). Expression of CNGβ1 protein 
rescued the expression of previously downregulated CNGα1 in the 
treated regions (Figure 6B) (and not outside of the treated area or in 
untreated Cngb1–/– eyes; data not shown and ref. 29), suggesting the 
formation of functional heterotetrameric CNG channel complex-
es. Further evidence that the CNG channel subunits had formed a 
functional channel complex was provided by ffERG and vision test-
ing, both of which showed a dramatic improvement in rod-medi-
ated function (described below). Figure 7A shows the ERG results 
for dog 14-055 (OD), with a much lowered response threshold and 
a waveform typical for WT dogs (although approximately one-third 
the amplitude of breed- and age-matched controls). The rod 5-Hz 
flicker response prior to treatment was almost nonexistent but was 
robust following gene therapy (Figure 7B). As a direct assessment 
of rod photoreceptor phototransduction, we performed fits of the 
leading edge of the rod a-wave using the Hood and Birch model 
based on the original Lamb and Pugh model (Figure 7C). These 
fits showed a significant increase in maximal receptor response 
(Rmax) over pretreatment values (P < 0.05, paired t test). ERG res-
cue was maintained in both eyes of dog 14-055 until the last time 
point assessed (18 months after injection). Plots of the mean a- and 
b-wave amplitudes against stimulus strength 3 months after treat-
ment showed a substantial improvement in the response threshold 
of the scotopic ERG (~1 log unit for the a-wave and >2 log units for 
the b-wave) (Figure 7, D and E) for all eyes treated with the higher 
dose. The ERG rescue was maintained over the long term, as illus-
trated in Figure 7, F and G (amplitudes of scotopic ERGs elicited by 
a flash of low luminance that resulted in a rod response and a 5-Hz 
flicker response, also indicative of rod responses).
All eyes treated with the higher titer had significantly 
improved vision at the lowest light level. When using the treated 
eye (eyes were tested in turn by covering the contralateral eye with 
an opaque contact lens), the dogs correctly chose the open exit 
100% of the time at the lowest light level 3 months after injection 
compared with a mean of 42% of the time for untreated controls 
(P = 1.3 × 10–5). Their exit times were also improved being a mean 
of 3 seconds 3 months after treatment compared with 28 seconds 
for the untreated controls (P = 1.0 × 10–4) (Figure 7, H and I). The 
improvement in vision testing outcomes was maintained in all 
treated dogs for the duration of the study (data not shown).
Figure 3. Cngb1–/– mice show a progressive loss of photoreceptor structure 
and function. (A) Age-related loss of the REC+ layer in Cngb1–/– mice com-
pared with WT mice, as measured by SD-OCT imaging. The colored vertical 
bars indicate the ages at which photopic ERG b-wave amplitudes were 
measured in C (mean of n = 4–6 for each time point). (B) IHC with a cone 
marker (cone arrestin) showing morphologically affected but still-persist-
ing cones after advanced thinning of the ONL (representative images from 
3 mice). Scale bar: 25 µm. (C) Photopic cone b-wave amplitudes of Cngb1–/– 
mice plotted against stimulus strength at 2, 6, and 8 months of age (mean 
of 4 for each time point). Data represent the mean ± SD. PW8, postnatal 
week 8; PW26, postnatal week 26; PW35, postnatal week 35.
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early age, followed by a slowly progressive age-related loss of cone 
function and, in humans, constriction of visual fields.
Preservation of the macula is a feature of this (Figure 2) 
and other forms of RP. The presence of an area centralis in the 
dog, with its similarity to the human macula, allows the study of 
changes in a region of higher photoreceptor density, which is an 
advantage over laboratory rodents, which do not have a compa-
rable retinal region. Like the finding of macular preservation in 
RP patients, Cngb1–/– dogs also showed a preserved REC+ thick-
ness in the area centralis and visual streak (Figure 4, A and B). 
The packing density of photoreceptors is highest in these regions, 
with peak cone density in the center of the region approaching 
that of the human macula (33). Measurement of the individual 
SD-OCT–detectable retinal layers that comprise the REC+ (OPL, 
ONL, ELM, MZ, EZ, outer segments, IZ, and RPE–Bruch’s com-
plex) (34) revealed that, unlike in the macula of human patients, 
there was an early loss of ONL thickness indicating an early loss 
of photoreceptor nuclei in the Cngb1–/– dog area centralis. The 
thickness of the REC+ layer was preserved as a result of mainte-
nance of the SD-OCT–detectable zones representing the photo-
receptor inner and outer segments and the interdigitation with 
the RPE. In the central part of the area centralis of the normal 
dog retina, the number of cones peaks, such that the numbers of 
rows of cone and rod nuclei are similar (33). Despite this higher 
number of cones, SD-OCT imaging shows a slight thinning 
of the ONL layer of the area centralis in normal dogs (33) (also 
see Supplemental Figure 7, bottom). As occurs in the equivalent 
human foveal region, the inner segments of canine cones in 
this region are thinner and elongated (33, 35). It is conceivable 
that the early ONL thinning in this region in the Cngb1–/– dog 
is accounted for by loss of central rods and that the high propor-
tion of cones with elongated inner and outer segments, compared 
with regions outside the area centralis, accounts for the mainte-
nance of the thickness of the corresponding SD-OCT layers and 
preservation of REC+ thickness in this region. Preservation of 
cones until later in the disease process may also explain the main-
tenance of EZ integrity in the area centralis. The EZ is believed 
to correspond with the distal end of the photoreceptor inner seg-
ments, perhaps reflecting the large number of mitochondria in 
this part of the photoreceptor (36). Loss of intensity or integrity of 
the EZ has been associated with deterioration of vision in humans 
with various retinal conditions (reviewed in ref. 37).
As is typical for RP, humans with RP45 show a hyperautoflu-
orescent macular ring on FAF imaging. This is suggested to rep-
resent an abnormal perifoveal accumulation of lipofuscin in the 
RPE associated with disease-related increased photoreceptor out-
er segment loss (38, 39). In our study, changes in the width of the 
hyperautofluorescence ring was detectable in patients who under-
went serial imaging, with differences being detectable over a period 
as short as 2 years (Figure 2). Likewise, the degree of  thinning of 
photoreceptor-attributable layers (REC+) on SD-OCT progressed 
within the same follow-up interval, however, thinning appeared to 
spatially precede the ring constriction in the patients observed in our 
study. These findings corroborate those of another study describ-
ing analogous thinning as well as a functional decline within the 
apparently unaffected area within the AF ring (38). The ring itself 
may therefore not be the earliest marker of photoreceptor dysfunc-
In vivo imaging showed a clear preservation of retinal struc-
ture and thickness in the treated region (Figure 8, A and D). Assess-
ment of the mean REC+ thickness in the treated retinal regions 
compared with the same retinal regions in untreated Cngb1–/– dogs 
showed that treatment preserved REC+ thickness (Figure 8, B and 
C). We observed an initial continuation of REC+ thinning for 3 to 
4 months after injection, after which it halted, and REC+ thickness 
was maintained and remained significantly thicker than in either 
the untreated region of the same eyes or in the eyes of untreated 
Cngb1–/– dogs (Figure 8B). The junction between the preserved 
treated retinal region and the adjacent untreated retinal region 
became more apparent over time. Within the treated area, the 
definition of the SD-OCT zones representing the photoreceptor 
inner and outer segments was clearly preserved in the treated 
areas, whereas in the untreated adjacent retinal areas, the zones 
could not be discerned (Figure 8, A and D). Dogs maintained for 
study for longer than 3 months after treatment had less AF in the 
injected retinal regions compared with the uninjected regions on 
FAF imaging (Figure 8, C and inset in D).
Discussion
Humans with CNGB1-related RP (12, 13, 16, 23), mice (Cngb1-X26) 
(27), and Cngb1–/– dogs with mutations that spare expression of the 
alternatively expressed GARP subunits share a similar phenotype 
characterized by a lack of rod-mediated retinal function from an 
Figure 4. Cngb1–/– dogs have a progressive retinal thinning with 
preservation of the REC+ in the area centralis. (A) Measurement of 
REC+, ONL, and inner segment/outer segment (IS/OS) layer thickness 
by SD-OCT cross-sectional images in a vertical plane through the area 
centralis, measured every 0.5 mm. The negative numbers are inferior 
to the area centralis. Control dogs: n = 3; Cngb1–/– affected dogs: n = 3 
dogs 6–7 months of age; n = 3 dogs 18–19 months of age; n = 1 dog 48 
months of age; n = 2 dogs 66–69 months of age. (B) Heatmaps demon-
strating preservation of photoreceptor thickness in the area centralis and 
horizontally along the visual streak. REC+ thickness in Cngb1–/– dogs of 
different ages compared with a control (WT) dog. n = 3 control dogs; n = 3 
Cngb1–/– dogs at 18 months of age; n = 1 Cngb1–/– dog at 48 months of age; 
and n = 2 Cngb1–/– dogs at 66 months of age. (C) Representative images of 
plastic-embedded semi-thin retinal samples from an 8-week-old control 
dog compared with samples from a Cngb1–/– dog. The inner segments of 
cones are located adjacent to the inner segments of rods in the control 
dog. Shortening of the rod inner segments in the Cngb1–/– dogs resulted 
in cone inner segments extending to the level of the rod outer segments. 
Rod outer segments appeared disorganized and deteriorated over the first 
28 months. Initially, cone inner segments appeared grossly normal and 
then, with rod loss, initially appeared widened (at 12 months) but then 
became shortened and atrophied (at 28 months). Sections (500-nm) were 
stained with epoxy tissue stain. Arrows indicate the cone inner segment. 
Scale bar: 20 μm. n = 4 control dogs; n = 1 Cngb1–/– dog at 2, 5, 12, and 28 
months of age; n = 2 Cngb1–/– dogs at 18 months of age. (D) Representa-
tive images of IHC with hCAR (labels the entire length of the cones) show 
well-preserved cone morphology in the younger animals. In the older 
Cngb1–/– affected dogs (18 and 30 months of age), the cones were still vis-
ible, albeit shortened. Scale bar: 20 μm. n = 2 control dogs; n = 2 Cngb1–/– 
dogs at 2 and 18 months of age; n = 1 Cngb1–/– dog at 12 and 30 months 
of age. (E) Representative transmission electron microscopic images of 
rods (R) and cones (C) show a reasonably normal arrangement of rod discs 
at 2 months of age in the Cngb1–/– dog, but by 12 months of age, the rod 
outer segments had deteriorated, but the cone outer segments appeared 
relatively normal. Scale bar: 2 μm. n = 4 controls; n = 1 Cngb1–/– dog at 2 
and 12 months of age.
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atively preserved visual function and acuity; however, this region 
was structurally abnormal, in that we detected a pattern of REC+ 
thickness that was significantly elevated above the normal range 
in healthy retinae. Interestingly, visual examination of this region 
on SD-OCT revealed shallower foveal depressions, an incomplete 
extrusion of the plexiform layers, and central vertical widening 
of the ONL in varying degrees across all patients (Supplemental 
Figure 3). These changes bore an apparent resemblance to fove-
al hyploplasia (44), though this is a developmental anomaly most 
often associated with X-linked ocular albinism (45) and has not 
been described previously as a clinical manifestation of RP. The 
underlying cause of this apparent thickening of the ONL may be 
biologically intrinsic to the pathogenesis of CNGβ1 pathogenesis, 
or perhaps a mechanical stretching of the inner retina due to the 
deterioration of the outer retinal layers, namely the EZ, as has 
been previously described in other RP patients (46).
Cngb1–/– dogs had a pattern of hyperautofluorescence that was 
different from that of the human patients, showing a small region 
tion in the retinae of RP patients; however, a direct correlation with 
structural changes in the outer retina and a consistent pattern of 
progression have been extensively demonstrated in heterogeneous 
RP cohorts (40–42). Therefore, although these morphological fea-
tures may individually be valid biomarkers of disease progression, 
they are likely reflective of different degenerative processes, par-
ticularly as both are derived from separate imaging modalities (32, 
43). A more in-depth understanding of the relationship between 
the morphological features seen on AF (488-nm excitation), which 
derive principally from the distribution of RPE lipofuscin, and pho-
toreceptor loss is warranted. Nevertheless, these features appeared 
to change rapidly enough in the patients in this study to suggest that 
they could be used as a plausible measure of therapeutic outcome 
for a future clinical therapy trial, although a more thorough assess-
ment of the natural history in a significantly larger cohort of patients 
with RP45 is needed to confirm this finding.
Consistent with the clinical characterization of RP, the 
CNGB1-RP patients in this study maintained a central area of rel-
Figure 5. Cone function slowly declines with age in the 
Cngb1–/– dog. (A) Photopic single-flash ERG tracings in 
response to the following stimuli in the light-adapted eye 
present on a background of 30 cd/m2: –0.4, 0.0, 0.4, 0.9, 
1.4, and 1.9 log cds/m2 (top to bottom tracings), and at the 
bottom, a photopic 33-Hz flicker response at 0.4 log cds/
m2. (B and C) Change in the mean (± SD) photopic a-wave (B) 
and b-wave (C) amplitudes in response to the 0.4 log cds/m2 
stimulus with age. The mean photopic a-wave amplitude for 
Cngb1–/– dogs was significantly lower at 42 and 66 months of 
age (P < 0.05, Student’s t test). The mean photopic b-wave 
was significantly reduced at 66 months of age (P < 0.01, 
Student’s t test). n = 2 Cngb1–/– dogs at each time point; n = 3 
controls at 14 and 36 months; and n = 2 controls at 72 months. 
(D and E) Results of vision testing showing the percentage of 
dogs that made the correct exit choice (D) and the time taken 
to exit (E). At all ages tested, the affected dogs had reduced 
visual function at the lowest light level. Bright light vision 
was maintained in all age groups tested. Control dogs: n = 6; 
Cngb1–/– dogs: n = 3 for 4-month-old and 12- to 24-month-old 
dogs and n = 4 for 36- to 48-month-old dogs.
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function but only a slow physical loss of rod photoreceptors. IHC 
showed that this therapy resulted in Cngb1 expression in out-
er segments at the earliest time point assessed (3 months after 
injection), and this was maintained for at least 23 months after 
injection, but only in the treated retinal regions (Figure 6A and 
Figure 8D, bottom). We found that the expression of Cnga1 was 
also increased, but only in the treated regions, confirming that 
CNGβ1 is required for the trafficking of CNGα1 to the rod outer 
segments (Figure 6B). Untreated Cngb1–/– dog retinae lacked 
expression of full-length Cngb1 and had very reduced CNGα1 
levels. The labeling of CNG subunits on IHC after gene therapy 
appeared to be similar to that in normal dogs. Therapy resulted 
in a dramatic and sustained improvement in rod-mediated ERG 
responses and in visual function at dim light levels.
This preliminary proof-of-concept study suggested that there 
was a dose effect: the first eye injected using a lower dose of vec-
tor showed less evidence of rescue than did eyes subsequently 
treated at a higher dose. A dose escalation study is required to 
establish the optimal dose for the greatest rescue without toxicity. 
We detected variations in the degree of ERG rescue among eyes, 
with several possible reasons including individual (biological) 
variation, age at injection, and the area of retina treated and thus 
the number of transduced rods contributing to the ffERG. Similar 
volumes of vector were injected, but, as is typical for subretinal 
injections, the extent of the retinal detachment (and thus the area 
treated) varied among eyes.
One dog (both eyes treated) maintained for longer-term 
study had sustained ERG rescue up to 18 months after injection 
(the last time point recorded), with no diminution. SD-OCT 
clearly showed an improvement in the treated area in the appear-
of brighter AF developing in young Cngb1–/– dogs in the center of 
the area centralis and then along the visual streak, with disease 
progression (Supplemental Figure 6B). The difference in AF pat-
terns between dogs and humans may reflect a species difference in 
the course of photoreceptor loss between different retinal regions. 
It is of interest that in gene therapy–treated dogs, by several 
months after treatment, we observed less AF in the treated region 
compared with that detected in the untreated region (Figure 8, C 
and D). This might reflect the reduction in photoreceptor death in 
the treated regions.
A possible histological explanation for the early loss of defini-
tion of the zones representing the photoreceptor inner and outer 
segments in the peripheral retina on SD-OCT imaging of Cngb1–/– 
dogs was the finding on semi-thin sections of a disruption of the usu-
ally sharp demarcation between photoreceptor inner segments and 
outer segment layers, with rod outer segments appearing alongside 
cone inner segments (Figure 4, C, D, and E). With the progression 
and loss of the rods, the remaining cone inner segments became 
wider in diameter and then progressively more stunted.
Photopic (cone-mediated) vision in Cngb1–/– dogs was well 
maintained (up to at least 66 months of age), despite the dimin-
ishing cone ERG amplitudes. It has been our experience that very 
few remaining functional cones are required in dog RP models 
for them to negotiate around obstacles in bright light conditions, 
and this degree of vision can still be the case even after cone ERG 
responses can no longer be detected (S.M. Petersen-Jones, unpub-
lished observations).
Currently, there is no definitive treatment for RP. We 
hypothesized that the Cngb1–/– dog would be a good candidate 
for gene augmentation therapy because of the early loss of rod 
Figure 6. Gene augmentation 
therapy results in appropriate 
rod Cngb1 expression and 
restores Cnga1 expression. 
(A) CNGβ1 (green: antibody 
targeted CNGβ1 distal to the 
mutation site) was expressed 
in the outer segments of the 
treated regions of Cngb1–/– 
retinae 3, 9, and 23 months 
after treatment. The untreated 
region from the retinae 3 
months after injection and 
the 28-month-old untreated 
Cngb1–/– retinae did not express 
full-length CNGβ1. (B) CNGα1 
(green) was expressed and 
correctly targeted to the photo-
receptor outer segments in 
the treated regions of Cngb1–/– 
retinae 3, 9, and 23 months 
after treatment, but was not 
detectable in the untreated 
region. Scale bar: 50 μm.
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Figure 7. Sustained rescue of rod function by gene therapy. (A–C) Scotopic ERGs before treatment and 3, 12, and 18 months after subretinal AAV5-hGRK1-
cCngb1 treatment (dog 14-055 right eye). (A) Luminance response series. Note the obvious lowering of the response threshold and increased a- and b-wave 
amplitudes (stimulus luminances ranged from –3.7 to 0.4 log cds/m2). (B) Scotopic 5-Hz flicker responses at –1.6 log cds/m2 luminance (vertical scale 
bars: 50 μV; horizontal scale bars: 50 ms). (C) Fit of the leading edge of the dark-adapted a-wave to the Hood and Birch model. The solid lines are the raw 
ERG data and the dotted lines the derived fits to the leading edge of the a-wave. (D and E) Mean (± SD) stimulus response ERG plots for scotopic a- and 
b-waves comparing unaffected control dogs (n = 4) with Cngb1–/– dogs before and 3-months after subretinal AAV5-hGRK1-cCngb1 treatment (n = 7). Com-
pared with before treatment, all mean a-wave responses were significantly improved (P < 0.05 and P < 0.01, 2-tailed, paired Student’s t test). The b-wave 
responses were also significantly improved (P < 0.05 to P <0.01, 2-tailed, paired Student’s t test), with the exception of the responses to the strongest 
stimuli (P = 0.052 and P = 0.054, 2-tailed, paired Student’s t test). (F and G) Duration of ERG rescue. Mean ± SD of scotopic b-wave in response to a stim-
ulus of –2 log cds/m2 (F) and scotopic 5-Hz flicker at –1.6 log cds/m2 luminance (G), with time after injection. The gray bar represents the mean amplitude 
of untreated dogs ± 2 SD. Number of treated eyes at each time point: before treatment (0), 1, 2, and 3 months, n = 7;4 and 5 months, n = 4; 6, 7, and 9 
months, n = 3; 12 and 18 months, n = 2. (H and I) Vision test results before versus 3 months after treatment. (H) Percentage of dogs that made the correct 
exit choice at each of 7 lighting levels. Pretreatment Cngb1–/– dogs made more exit choice errors at the dimmer light levels, and these dogs almost always 
chose correctly 3 months after gene augmentation. The improvement was significant at the lowest light intensity (P < 0.0001, 2-tailed, paired Student’s t 
test). (I) Time to exit. Prior to treatment, the Cngb1–/– dogs were slower to exit at the low light levels, and 3 months after treatment, the dogs were faster 
to exit at the low light levels. The difference was significant at the lowest light level (P < 0.001, 2-tailed, paired Student’s t test).
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Figure 8. Retinal structure is preserved in gene therapy–treated retinal regions in Cngb1–/– dogs. (A) SD-OCT cross-sectional images of the retinal region 
of an AAV5-hGRK1-cCgnb1–treated Cngb1–/– dog showing preservation of the retinal layers. In addition to ONL preservation, the ELM, EZ, and IZ appear to 
have better definition compared with untreated Cngb1–/– dogs. A WT control retina is shown for comparison. IR, inner retina; TR, total retina. (B) Plot of 
the mean thickness of the REC+ layer with age in Cngb1–/– treated retinae (n = 2) compared with Cngb1–/– untreated and unaffected dog retinae. The first 
time point of the Cngb1–/– measurement was 1 month after treatment. The untreated Cngb1–/– retina had a progressive, age-related decline in thickness. 
The treated eyes showed an initial decline in thickness of the REC+, like the untreated eyes, but then plateaued to remain significantly thicker than the 
REC+ layer of the untreated eye (P = 0.019, 2-tailed Student’s t test, 17–18 months of age). n = 3 untreated Cngb1–/– dogs. Data represent the mean ± SD. (C) 
FAF cSLO imaging of a treated eye 23 months after injection. The noninjected retinal region had a higher level of AF than did the treated (injected) region. 
Heatmap shows REC+ layer thickness preservation in the treated area of the same eye. (D) Cross-sectional SD-OCT images across the junction between 
injected and noninjected areas of the same eye as in C, showing a thinning of the ONL in the noninjected area (boundary is indicated by a white arrow). 
Also note the better definition of the ELM zone, the EZ, and the IZ zone on the image in the injected region. IHC image of the same region shows that 
Cngb1 expression stopped abruptly at the edge of the injected area (white arrow). Scale bars: 100 μm (A), 200 μm (D, top), and 100 μm (D, bottom). 
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Methods
Human patients
Complete ophthalmic examinations included slit-lamp and dilated 
fundus examinations. Vision was assessed by the measurement of 
BCVA (Snellen).
SD-OCT scans and corresponding infrared reflectance fundus 
images were acquired using a Spectralis HRA+OCT (Heidelberg 
Engineering). FAF images were obtained using the Heidelberg Retina 
Angiograph 2 confocal scanning laser ophthalmoscope (cSLO) (Hei-
delberg Engineering,). The images were acquired by illuminating the 
fundus with an argon laser source (488-nm excitation) and viewing the 
resultant fluorescence through a band-pass filter with a short wave-
length cutoff at 495 nm. Ultra-widefield AF (532-nm excitation) and 
color images for patient 8 were acquired with an Optos 200Tx cSLO 
(Optos PLC). Color fundus photos were obtained with a FF450plus 
Fundus Camera (Carl Zeiss Meditec). Retinal image analyses were 
carried out using Heidelberg Explorer software (HEYEX). Constric-
tion of the hyperautofluorescence ring on FAF images was assessed by 
comparing the difference in areas (mm2) within the external ring bor-
der between baseline and subsequent examinations. REC+ thickness 
was assessed in single 9-mm and cube (20 × 15/6.2 mm × 4.6 mm, 19 
b-scans) high-resolution (HR) SD-OCT scans through the fovea and 
over the macula, respectively, using HEYEX segmentation software. 
Two groups of age-matched (20–30 years and 30–40 years) healthy 
controls were measured and 95% CIs calculated for comparison.
ffERGs were recorded with the Diagnosys Espion Electrophysiol-
ogy System (Diagnosys) using standard techniques of the Internation-
al Society for Clinical Electrophysiology of Vision (ISCEV) (48).
Genetic screenings in all patients were carried out at molec-
ular diagnostics laboratories approved by the Clinical Laboratory 
Improvement Amendments (CLIA). Patients 1 and 2 were tested 
under the National Ophthalmic Disease Genotyping Network (eye-
GENE), and direct sequencing of exon 31 of the CNGB1 gene was per-
formed. Patients 3 and 5 were first tested by the Asper Ophthalmics 
(Estonia) Autosomal Recessive Retinitis Pigmentosa Arrayed Primer 
Extension (APEX) microarray chip (594 mutations on 19 genes) and 
then by the Massachusetts Eye and Ear Ocular Genomic Institute 
(Boston, Massachusetts, USA). Patient 4 was tested with Retinitis 
Pigmentosa Tier 1 Panel screening by the Casey Eye Institute Molec-
ular Diagnostic Laboratory (Portland, Oregon, USA). Segregation in 
3 unaffected siblings and both parents of patient 4 was consistent 
with biallelic inheritance, with only the proband harboring both 
CNGB1 variants. Patients 3, 5, and 6 were tested at the Massachusetts 
Eye and Ear Ocular Genomic Institute using Sanger sequencing of 
all CNGB1 exons (ABI BIG DYE chemistry and ABI 3100 automated 
sequencer) and also using Retinitis Pigmentosa Tier 1 Panel screen-
ing performed by the Casey Eye Institute Molecular Diagnostic Lab-
oratory. Parents’ samples were tested for all 3 patients, which was 
consistent with biallelic inheritance of the variant in each respec-
tive patient. Patients 7 and 8 underwent whole-exome sequencing 
at the Columbia University Laboratory for Personalized Genomic 
Medicine using the Agilent SureSelectXT Human All Exon V5+UTRs 
capture method and Illumina HiSeq 2500 sequencing technology. 
Pathogenicity of found variants data were analyzed using NextGENe 
software (SoftGenetics). The variant number is in accordance with 
the NCBI’s GenBank NM_001297.4 (with cDNA numbering start-
ance of the zones that represent the inner and outer segments of 
the photoreceptors. We found that the EZ and IZ were clearly vis-
ible in the treated area, but their integrity was lost outside of the 
treated region. SD-OCT measurements of the REC+ layer showed 
that, in the initial few months after treatment, some progressive 
thinning occurred but was halted and that REC+ thickness was 
subsequently conserved in the treated retinal regions but not in 
untreated areas, where degeneration occurred to an extent simi-
lar to that seen in untreated control Cngb1–/– dogs. We confirmed 
the preservation of photoreceptors in the treated regions by reti-
nal histology. The initial loss of REC+ thickness in the period fol-
lowing subretinal injection may be due to a combination of the 
time it takes for transgene expression to become established and 
the loss of rods that were either not transduced, expressed inad-
equate levels of CNGβ1, or were already irreversibly on the path 
to cell death. Loss of photoreceptors in Cngb1–/– dogs and mice 
occurs more slowly than it does in some other RP models (e.g., 
those with phosphodiesterase 6 mutations [ref. 47]), and for this 
reason, treated animals need to be maintained for adequate peri-
ods of time after initiation of therapy to allow for assessment of 
the structural preservation resulting from therapy.
These promising initial gene therapy results support further 
investigation of the long-term rescue of rod function and mainte-
nance of retinal structure. Optimization of the vector, both in terms 
of the specific vector construct and optimal vector dose, is also war-
ranted. Furthermore, in planning for the potential future treatment 
of human patients, it will be important to study the efficacy of ther-
apy applied at different disease stages. In the current study, younger 
dogs were treated prior to major loss of rod photoreceptors.
Treatment in humans should, at the very least, be aimed at 
preserving cone function. Many forms of RP result from mutations 
in genes expressed in rod photoreceptors, leading to rod photore-
ceptor death, which is followed by an inevitable secondary loss of 
cones. Gene augmentation for the rod-led diseases will only be 
successful while there are still sufficient rods remaining to support 
continued cone survival. Thus, this requires early diagnosis and 
treatment. With RP45, the presence of nyctalopia in childhood 
offers the opportunity for early identification of patients who are 
suitable for gene augmentation, while there is still a population of 
potentially rescuable rods.
In summary, we show that patients with mutations in CNGB1 
have night blindness from childhood, with a slow loss of photore-
ceptors. Their phenotype is similar to that of the Cngb1-X26 mouse 
and the Cngb1–/– dog. Our preliminary study of gene augmentation 
therapy in Cngb1–/– dogs showed a robust improvement in rod func-
tion, with evidence of photoreceptor preservation and improve-
ment in photoreceptor morphology. The slow loss of photorecep-
tors, despite an early absence of night vision, provides a potentially 
large therapeutic window of opportunity. This finding, coupled 
with the successful gene therapy reported in the Cngb1-X26 mouse 
(28) and now the Cngb1–/– dog, make this an attractive form of RP 
for gene therapy. Potential outcome measures for human patients 
could include improvement in rod-mediated ERG responses and 
rod vision in younger patients, who have a sufficient population 
of rods available to rescue and contribute to a rod ERG, and halt-
ing of progressive changes in the hyperautofluorescence zone and 
thickness of REC+ as indicators of structural preservation.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 0 3jci.org   Volume 128   Number 1   January 2018
neering) in combination with optic lenses. OCT scans were con-
ducted with a 12° circular scan mode centered at the optic nerve 
head. Quantification of the REC+ layer was performed as described 
previously (55).
Wide-field color fundus images of dogs were captured using a 
RetCam II Video Fundus Camera (Clarity Medical). cSLO imaging 
and SD-OCT of dogs were performed using a Spectralis OCT+HRA. 
High-resolution cross-sectional images were obtained by line and vol-
ume scanning.
Vision testing of dogs
Vision testing of dogs was performed using a previously described 
4-choice vision-testing device (56, 57). Briefly, dogs were placed in the 
central box of the vision-testing device from which there were 4 tunnel 
exits. The far ends of 3 of the exits were blocked, and 1 was left open. 
The open exit was randomly chosen for each run. Performance was 
tested under 7 lighting settings, ranging from bright to dim light levels. 
The time to exit the device and the first exit chosen were recorded. 
The mean correct choice and time to exit were calculated over 14 runs 
per light intensity. Vision in each eye of the gene therapy–treated dogs 
was tested separately by placing an opaque contact lens to block vision 
from the contralateral eye.
IHC
Mouse eyes were processed for IHC as previously described (28). 
Vertical cryosections (10-μm) were stained using a rabbit anti-mouse 
cone arrestin antibody (1:300) (58) (a gift of Wolfgang Baehr, Univer-
sity of Utah School of Medicine, Salt Lake City, UT, USA).
Canine eyes were processed for frozen IHC following previous-
ly described methods (29, 59). The following primary antibodies 
were used: rabbit polyclonal anti-CNGβ1 targeting the C-terminus 
(downstream of the canine mutation site) (1:500) (HPA039159; 
Sigma-Aldrich); rabbit polyclonal anti-CNGB1, generated to amino 
acids 574–763 (60), which is downstream of the GARP region and 
upstream of the canine Cngb1 mutation (1:2,000) (FPc21K, a gift of 
Frank Müller, Institute of Complex Systems, Cellular Biophysics, 
ICS-4, Forschungszentrum Jülich, Germany); mouse monoclonal 
anti-CNGα1 (1:10) (a gift of Bob Molday, University of British Colum-
bia, Vancouver, British Columbia, Canada) (61); mouse monoclonal 
anti-rhodopsin (MS1233PABX, rhodopsin Ab-1, RetP1; Thermo Fisher 
Scientific); and anti-human cone arrestin (hCAR) (1:10,000) (a gift of 
Cheryl Craft, Keck Medical School of University of Southern Califor-
nia & USC Roski Eye Institute, Los Angeles, California) (62).
Plastic-embedded histological sectioning and electron microscopy
Canine eyes for plastic-embedded sectioning and transmission 
electron microscopy were fixed as previously described (47). 
Regional retinal sections were dissected, embedded in agarose, 
post-fixed in 2% osmium tetroxide for 15 minutes, dehydrated in 
acetone, and then infused with Spurr resin (63). Semi-thin sections 
(500-nm) were stained with epoxy tissue stain (Electron Micros-
copy Sciences), and thin sections (70- to 100-nm) were captured 
on copper grids and stained with 4% uranyl acetate and then Reyn-
olds lead citrate. Semi-thin sections were imaged on a light micro-
scope (Nikon Eclipse 80i; Nikon Instruments). Thin sections were 
imaged on a JEOL 100CX transmission electron microscope with a 
Gatan ORIUS camera.
ing with the A of the ATG start codon) and NP_001288.3. Variants 
were considered novel if not previously reported and not present in 
the NCBI’s dbSNP (http://ncbi.nlm.nih.gov/projects/SNP/), Exome 
Variant Server (EVS; http://evs.gs.washington.edu/EVS/), or the 
Exome Aggregation (ExAC) database (http://exac.broadinstitute.
org). Splice prediction was performed using the Human Splicing 
Finder (http://www.umd.be/HSF3/) (31). A minigene assay was per-
formed to investigate a novel splice variant in patient 4 (protocol is 
found in the Supplemental Methods).
Animal studies
Mice. Cngb1-X26 mice as previously described (27) (http://www.infor-
matics.jax.org/allele/MGI:3527896) were used in this study. Control 
experiments were conducted using mice with the same genetic back-
ground. The mouse line was on a mixed background of 129/SvJ and 
C57-BL6/N, without the rd8 (Crb1) mutation.
Dogs. The dogs used in this study were maintained in a colony at 
the Michigan State University Comparative Ophthalmology Labora-
tory. Dogs with a spontaneously occurring mutation in canine Cngb1 
were identified and bred with laboratory beagles to create a breeding 
colony in which the Cngb1 mutation segregated the providing dogs 
that were either homozygous or heterozygous for the mutant allele or 
homozygous for the WT allele (29).
Retinal RT-PCR
RT-PCR of canine retinal tissues was performed using standard 
protocols. Expression levels of retinal transcripts were normalized 
to succinate dehydrogenase (Sdha) mRNA levels. Following RNA 
extraction using an RNeasy Mini Kit (QIAGEN) and a cDNA synthe-
sis (3′ RACE Kit (Invitrogen, Thermo Fisher Scientific) according to 
the manufacturers’ instructions, the following mRNA levels were 
analyzed via real time quantitative PCR (Applied Biosystems StepOne 
Fast Machine): Cngb1 (Cngb1 forward: GGACATCACCGTGTTCCAG; 
Cngb1 reverse: TGTCCATCTTAAAGCGACGAG); Cnga1 (Cnga1 for-
ward: TCCCAATGTGATTGTTCCAG; Cnga1 reverse: TCAAACAT-
GGAGGCACTGTC); Pde6a (Pde6a forward: CCACGTGAAGTGT-
GACAATG; Cnga1 reverse: AGCTCTCCTTGCAGGATCTC); and 
Sdha (Sdha forward: CGGTCCATGACTCTGGAAAT; Sdha reverse: 
GCAACTGCAGGTACACATGG).
To investigate the effect of the mutation in canine Cngb1 on splic-
ing, retinal cDNA was amplified using primers flanking canine Cngb1 
exon 26 (forward primer: AGGGTTTTCCCAGTCACGACCGG-
CCTACCTGCTCTACAGT; this primer included a tag to allow quanti-
fication if required; reverse primer: ACCAGGTCTTGACACGGTTC). 
Gel-purified amplicons were sent to Michigan State University’s 
Research Technology Support Facility for Sanger dideoxy sequencing 
on an ABI 3730 Genetic Analyzer (Applied Biosystems).
Animal ERG
ERGs in mice were performed as previously described (49, 50). ERGs 
in dogs were recorded as previously described (51, 52). Modeling of the 
leading edge of the dark-adapted a-wave was performed as described 
by Hood and Birch (53, 54).
Animal retinal imaging
SD-OCT of mice was performed as previously described (28, 55), 
using an adapted Spectralis HRA+OCT system (Heidelberg Engi-
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of patients. EB designed and completed the minigene assay. CS 
implemented and interpreted mouse experiments. MWS imple-
mented and interpreted mouse experiments. AVL conducted 
studies of patients and analyzed human data. SM designed and 
interpreted mouse experiments and wrote the manuscript. WWH 
designed and developed viral vectors and edited the manuscript. 
SHT coordinated and analyzed human patient data.
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Gene therapy
The recombinant AAV2/5 vector with the canine Cngb1 cDNA con-
trolled by a human G protein–coupled receptor kinase 1 (GRK1) pro-
moter (AAV5-hGRK1-cCngb1) (Supplemental Figure 10) was manufac-
tured using previously published methods (64). AAV5-hGRK1-cCngb1 
was delivered subretinally into 8 eyes of 5 dogs as previously described 
(65). Supplemental Table 2 provides details on the dogs used for 
gene therapy in the study.
Statistics
P values were calculated using the statistical software SigmaPlot, 
version 12 (Systsat Software). Data were analyzed for normality 
and equal variance. If the data passed normality and variance tests, 
a Student’s t test was applied. Mean ERG values and vision testing 
before and after treatment were determined using a paired, 2-tailed 
Student’s t test. Nonparametric data were analyzed using a non-
parametric t test (unequal variance) or a Mann-Whitney U sum test 
(not normally distributed). A P value of less than 0.05 was consid-
ered statistically significant.
Study approval
Patients 1, 2, 7, and 8 were recruited at the CUMC and provided 
informed consent prior to their enrollment under the IRB-approved 
protocol AAAI9906 of Columbia University. Patients 3 and 4 were 
recruited at WEH and provided informed consent under the IRB- 
approved protocol 17-616EE of WEH. Patients 5 and 6 were examined 
at WEH and also at the CUMC. All study procedures adhered to the 
tenets established by the Declaration of Helsinki.
All procedures involving mice were performed with the permis-
sion of the Regierung von Oberbayern (Government of Upper Bavaria)
and those involving dogs were approved by the IACUC of Michigan 
State University. All animal experimentation was conducted in accor-
dance with the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Vision Research.
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